Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; carrageenan; gelatin; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; indigo carmine; titanium dioxide; purified talc; colloidal anhydrous silica - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ceritinib, quantity: 150 mg - capsule, hard - excipient ingredients: gelatin; magnesium stearate; sodium starch glycollate type a; hyprolose; colloidal anhydrous silica; indigo carmine; microcrystalline cellulose; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - zykadia is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - pirfenidone, quantity: 267 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; gelatin; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; iron oxide yellow; iron oxide red; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - esbriet is indicated for the treatment of idiopathic pulmonary fibrosis (ipf)

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 12.25 mg (equivalent: lenvatinib, qty 10 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; iron oxide yellow; purified talc; iron oxide red; calcium carbonate; propylene glycol; hyprolose; mannitol; potassium hydroxide; titanium dioxide; hypromellose; iron oxide black; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - lenvatinib mesilate, quantity: 4.9 mg (equivalent: lenvatinib, qty 4 mg) - capsule, hard - excipient ingredients: iron oxide yellow; propylene glycol; potassium hydroxide; mannitol; iron oxide black; titanium dioxide; hypromellose; purified talc; iron oxide red; calcium carbonate; microcrystalline cellulose; hyprolose; shellac - endometrial carcinoma lenvima, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.,differentiated thyroid cancer (dtc) lenvima is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (rai) refractory differentiated thyroid cancer (dtc).,renal cell carcinoma (rcc) lenvima, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc).,lenvima, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,hepatocellular carcinoma (hcc) lenvima is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: carrageenan; titanium dioxide; sodium lauryl sulfate; gelatin; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow; purified talc - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; carrageenan; gelatin; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; indigo carmine; titanium dioxide; purified talc; colloidal anhydrous silica - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; povidone; microcrystalline cellulose; purified water; sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; magnesium stearate; iron oxide yellow; butan-1-ol; shellac; industrial methylated spirit; iron oxide black; lecithin; xanthan gum; glyceryl monostearate; benzoic acid; methylcellulose; simethicone; glyceryl distearate; peg-10 stearate; sorbic acid; dimeticone 5000 - imulate is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. imulate is indicated for the prophylaxis of organ rejection in paediatric patients with a body surface area of greater than or equal to 1.25 meters square receiving allogeneic renal transplants (refer dosage and administration section).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; brilliant scarlet 4r; patent blue v; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks. (see adverse reactions).

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; silicon dioxide; magnesium stearate; maize starch; titanium dioxide; potable water; gelatin; propylene glycol; purified water; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; potassium hydroxide; iron oxide black - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggests that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of acute phase cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal canidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oesophageal canidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea crur